Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.
Pierre-Antoine JugeSteven GazalArnaud ConstantinXavier MarietteBernard CombeJacques TebibMaxime DougadosJean SibiliaXavier Le LoetPhilippe DieudéPublished in: RMD open (2017)
Our results support the contribution of the IRF5, SPP1 and TNFSF13B genotypic combination in the response to RTX for RA at W24.